Details of Disease

General Information of Disease (ID: DIS3AOQ7)

• Disease Name: Aerodigestive tract cancer
• Synonyms: GI tumour; GI tumor; malignant neoplasm of digestive system; malignant gastrointestinal system neoplasm; malignant gastrointestinal neoplasm; malignant digestive system neoplasm; gastrointestinal tract cancer; gastrointestinal system cancer; digestive system cancer; cancer of digestive system
• Disease Class: 2C29: Malignant respiratory system neoplasm
• Definition: A primary or metastatic malignant neoplasm involving any part of the digestive system.
• Disease Hierarchy:
  DIS7JDYJ: Gastrointestinal disease
  DISAT1Z9: Advanced cancer
  DISPOJCT: Digestive system neoplasm
  DIS3AOQ7: Aerodigestive tract cancer
• ICD Code:
  ICD-11: ICD-11: 2C29.Z
  Expand ICD-9: 1.40E+38
• Disease Identifiers:
  MONDO ID: MONDO_0002516
  MESH ID: D004067
  UMLS CUI: C0751075
  MedGen ID: 148231
  SNOMED CT ID: 448675008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
INO-3106	DMRO4CD	Phase 1	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GHSR	TTWDC17	Strong	Biomarker	[2]
MAGEC2	TTKGUEB	Strong	Biomarker	[3]
NEK2	TT3VZ24	Strong	Biomarker	[4]
TYMS	TTP1UKZ	Strong	Biomarker	[5]

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BRINP1	OTEUVSCP	Strong	Altered Expression	[6]
CCAR2	OTLUDG5T	Strong	Altered Expression	[6]
CRKL	OTOYSD1R	Strong	Biomarker	[7]
CYRIB	OTLRN4L1	Strong	Biomarker	[8]
FLOT1	OT0JPPJZ	Strong	Biomarker	[9]
RSPO2	OT3HHXU0	Strong	Biomarker	[10]
SPOP	OTP0107S	Strong	Altered Expression	[11]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Involvement of ghrelin-growth hormone secretagogue receptor system in pathoclinical profiles of digestive system cancer.Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):992-8. doi: 10.1111/j.1745-7270.2007.00360.x.
• [3] Novel role of microRNA-126 in digestive system cancers: From bench to bedside.Oncol Lett. 2019 Jan;17(1):31-41. doi: 10.3892/ol.2018.9639. Epub 2018 Oct 29.
• [4] Prognostic value of NEK2 overexpression in digestive system cancers: a meta-analysis and systematic review.Onco Targets Ther. 2018 Oct 18;11:7169-7178. doi: 10.2147/OTT.S169911. eCollection 2018.
• [5] Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.Clin Cancer Res. 2008 Feb 15;14(4):1059-64. doi: 10.1158/1078-0432.CCR-07-1513.
• [6] Deleted in Breast Cancer 1 as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-Analysis.J Cancer. 2019 Mar 3;10(7):1633-1641. doi: 10.7150/jca.26935. eCollection 2019.
• [7] Downregulation of CRKL expression can inhibit tumorigenesis in colon cancer.Front Biosci (Landmark Ed). 2014 Jan 1;19(3):528-34. doi: 10.2741/4223.
• [8] ZFR promotes cell proliferation and tumor development in colorectal and liver cancers.Biochem Biophys Res Commun. 2019 Jun 11;513(4):1027-1034. doi: 10.1016/j.bbrc.2019.04.103. Epub 2019 Apr 19.
• [9] Prognostic value of flotillins (flotillin-1 and flotillin-2) in human cancers: A meta-analysis.Clin Chim Acta. 2018 Jun;481:90-98. doi: 10.1016/j.cca.2018.02.036. Epub 2018 Feb 28.
• [10] Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor.Sci Rep. 2018 Sep 24;8(1):14244. doi: 10.1038/s41598-018-32652-3.
• [11] The association of speckle-type POZ protein with lymph node metastasis and prognosis in cancer patients: A meta-analysis.Medicine (Baltimore). 2019 Oct;98(40):e17439. doi: 10.1097/MD.0000000000017439.